TABLE 5

Symptom Duration According to Study Group During 6-Month Follow-up Period

Symptom Duration
PlaceboLactobacillus acidophilusL acidophilus/Bifidobacterium lactis
N104110112
Mean ± SD, d6.5 ± 7.34.5 ± 4.73.4 ± 3.7
Reduction vs placebo, %NA31.847.7
25th percentile, d111
50th percentile, d432
75th percentile, d1065
  • Cumulative duration of symptoms was modeled by using linear regression as a function of study group and age. Differences reflect the regression coefficients in such models accounting for the effects of age. Age-adjusted differences (mean ± SD) were as follows: L acidophilus/B lactis versus placebo, −3.2 ± 0.76 days (P < .001); L acidophilus versus placebo, −2.17 ± 0.71 days (P = .0023); L acidophilus/B lactis versus L acidophilus, −1.06 ± 0.81 (P = .195).